This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://localhost/temp/predkladatel/
n18http://linked.opendata.cz/resource/domain/vavai/projekt/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n10http://linked.opendata.cz/ontology/domain/vavai/
n5http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11130%2F09%3A5356%21RIV10-GA0-11130___/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11130%2F09%3A5356%21RIV10-GA0-11130___
rdf:type
n10:Vysledek skos:Concept
dcterms:description
Immunotherapy has emerged as another treatment modality in cancer. The goal of immunotherapy in advanced cancer patients does not have to be the complete eradication of tumor cells but rather the restoration of a dynamic balance between tumor cells and the immune response. Appropriate combination of tumor mass reduction (by surgery and/or chemotherapy) and neutralization of tumor-induced immunosuppression might set the right conditions for the induction of anti-tumor immune response by active immunotherapy. We review experimental basis and key concepts of combined chemo-immunotherapy and document its principles in the case report of patient with hormone refractory metastatic prostate cancer with sinister prognosis. Because of the high frequency of circulating Tregs in our patients, we first administered metronomic cyclophosphamide. After obtaining IRB approval, we started regular vaccinations with dendritic cells (DCs) loaded with killed prostate cancer cells. In accordance with the principles of com Immunotherapy has emerged as another treatment modality in cancer. The goal of immunotherapy in advanced cancer patients does not have to be the complete eradication of tumor cells but rather the restoration of a dynamic balance between tumor cells and the immune response. Appropriate combination of tumor mass reduction (by surgery and/or chemotherapy) and neutralization of tumor-induced immunosuppression might set the right conditions for the induction of anti-tumor immune response by active immunotherapy. We review experimental basis and key concepts of combined chemo-immunotherapy and document its principles in the case report of patient with hormone refractory metastatic prostate cancer with sinister prognosis. Because of the high frequency of circulating Tregs in our patients, we first administered metronomic cyclophosphamide. After obtaining IRB approval, we started regular vaccinations with dendritic cells (DCs) loaded with killed prostate cancer cells. In accordance with the principles of com
dcterms:title
FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer
skos:prefLabel
FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer
skos:notation
RIV/00216208:11130/09:5356!RIV10-GA0-11130___
n3:aktivita
n14:Z n14:P
n3:aktivity
P(GA310/08/0838), Z(MSM0021620812)
n3:cisloPeriodika
1
n3:dodaniDat
n7:2010
n3:domaciTvurceVysledku
n9:5285593 n9:7629419 n9:5730244 n9:1110047 n9:5239249 n9:7674597 n9:1287362 n9:9151915 n9:3605736 n9:3785769 n9:8086478 n9:6435467
n3:druhVysledku
n17:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n16:predkladatel
n3:idSjednocenehoVysledku
315315
n3:idVysledku
RIV/00216208:11130/09:5356
n3:jazykVysledku
n4:eng
n3:klicovaSlova
Dendritic cells; Cancer immunotherapy; Prostate cancer; Chemo-immunotherapy; PSA; regulatory t-cells; dying tumor-cells; dendritic cells; immune-responses; ovarian-cancer; chemotherapy; exposure; immunotherapy; calreticulin; vaccine
n3:klicoveSlovo
n8:ovarian-cancer n8:regulatory%20t-cells n8:PSA n8:Dendritic%20cells n8:calreticulin n8:immune-responses n8:dying%20tumor-cells n8:Chemo-immunotherapy n8:exposure n8:Cancer%20immunotherapy n8:chemotherapy n8:dendritic%20cells n8:Prostate%20cancer n8:immunotherapy n8:vaccine
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[93483A14B45F]
n3:nazevZdroje
Clinical Immunology
n3:obor
n19:EC
n3:pocetDomacichTvurcuVysledku
12
n3:pocetTvurcuVysledku
13
n3:projekt
n18:GA310%2F08%2F0838
n3:rokUplatneniVysledku
n7:2009
n3:svazekPeriodika
131
n3:tvurceVysledku
Ulčová, Hana Budinský, Vít Prausová, Jana Špíšek, Radek Minárik, Ivo Šedivá, Anna Lašťovička, Jan Rožková, Daniela Podrazil, Michal Bartůňková, Jiřina Linke, Zdeněk Tišerová, Hana Fučíková, Jitka
n3:wos
000264835000001
n3:zamer
n5:MSM0021620812
s:issn
1521-6616
s:numberOfPages
10
n11:organizacniJednotka
11130